Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MVA 5T4

Next Previous
Drug Profile

MVA 5T4

Alternative Names: 5T4 cancer vaccine; Cancer vaccine - Oxford Biomedica; Modified vaccinia Ankara 5T4; MVA-5T4; MVA-h 5T4; OBA 1 cancer vaccine; OXB-301; Recombinant modified vaccinia Ankara 5T4 vaccine; rV-5T4-VAC; SAR-109659; TroVax

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oxford BioMedica
  • Developer Cardiff University; Oxford BioMedica; University College London; Wales Cancer Trials Unit
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Malignant-mesothelioma; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 19 Sep 2020 Efficacy data from the phase II TRIOC trial in Ovarian cancer presented at the 45th European Society for Medical Oncology Congress (ESMO-2020)
  • 11 Jul 2019 Discontinued - Phase-II for Colorectal cancer (Inoperable/Unresectable, Metastatic disease) in United Kingdom (IM) (Oxford BioMedica pipeline - July 2019)
  • 11 Jul 2019 Discontinued - Phase-II for Malignant mesothelioma (Combination therapy, First-line therapy) in United Kingdom (IM) (Oxford BioMedica pipeline - July 2019)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top